Es gab 50 kürzliche Insider-Transaktionen für Olema Pharmaceuticals, Inc. (OLMA), darunter 23 Käufe und 18 Verkäufe. Die gesamten Insider-Käufe beliefen sich auf $24.66M und die gesamten Insider-Verkäufe auf $15.35M.
Bedeutende Insider mit kürzlicher Aktivität umfassen Mitchell Shawnte, Myles David C., Bohen Sean. Insider-Transaktionen können Einblicke geben, wie die Unternehmensführung die Bewertung und Zukunftsaussichten der Aktie einschätzt.
Insider-Transaktionen — OLMA
| Datum |
Name |
Funktion |
Transaktionsart |
Aktien |
Ø Preis |
Wert |
Gehaltene Aktien |
| 2026-03-04 |
Mitchell Shawnte |
Chief Legal Officer |
Informierter Verkauf |
233 |
$24.69 |
$5.75K |
- |
| 2026-03-03 |
Mitchell Shawnte |
Chief Legal Officer |
Informierter Verkauf |
15,000 |
$23.01 |
$345.15K |
- |
| 2026-02-02 |
Mitchell Shawnte |
Chief Legal Officer |
RSU-Zuteilung |
56,250 |
$25.65 |
$1.44M |
56,250 |
| 2026-02-02 |
Myles David C. |
Ch. Discov. & Non-clin Dev Off |
RSU-Zuteilung |
106,250 |
$25.65 |
$2.73M |
106,250 |
| 2026-02-02 |
Bohen Sean |
President and CEO |
RSU-Zuteilung |
275,000 |
$25.65 |
$7.05M |
275,000 |
| 2026-02-02 |
Zojwalla Naseem |
Chief Medical Officer |
RSU-Zuteilung |
106,250 |
$25.65 |
$2.73M |
106,250 |
| 2026-02-02 |
Austin Sasha Lu |
VP of Finance and Controller |
RSU-Zuteilung |
11,700 |
- |
- |
16,188 |
| 2026-02-01 |
Austin Sasha Lu |
VP of Finance and Controller |
Unbekannt |
13,000 |
$2.44 |
$31.72K |
- |
| 2026-01-30 |
Austin Sasha Lu |
VP of Finance and Controller |
Unbekannt |
45,000 |
$4.37 |
$196.65K |
- |
| 2026-01-20 |
Harmon Cyrus |
Director |
Informierter Verkauf |
10,000 |
$26.88 |
$268.8K |
727,770 |
| 2026-01-15 |
Kovacs Shane William Charles |
Ch. Operating & Financial Off. |
Informierter Verkauf |
100,000 |
$28.73 |
$2.87M |
139,727 |
| 2026-01-14 |
Myles David C. |
Ch. Discov. & Non-clin Dev Off |
Optionsausübung (Verkauf) |
50,000 |
$4.87 |
$243.5K |
50,000 |
| 2026-01-14 |
Harmon Cyrus |
Director |
Informierter Verkauf |
3,489 |
$29.12 |
$101.6K |
737,770 |
| 2026-01-13 |
Myles David C. |
Ch. Discov. & Non-clin Dev Off |
Optionsausübung (Verkauf) |
50,000 |
$4.87 |
$243.5K |
100,000 |
| 2026-01-13 |
Kovacs Shane William Charles |
Ch. Operating & Financial Off. |
Informierter Verkauf |
3,822 |
$28.01 |
$107.05K |
239,727 |
| 2026-01-12 |
Myles David C. |
Ch. Discov. & Non-clin Dev Off |
Informierter Verkauf |
10,000 |
$28.34 |
$283.4K |
144,846 |
| 2025-12-26 |
Bohen Sean |
President and CEO |
Schenkung (gegeben) |
8,500 |
- |
- |
237,650 |
| 2025-12-23 |
Zojwalla Naseem |
Chief Medical Officer |
Informierter Verkauf |
99,509 |
$27.66 |
$2.75M |
4,488 |
| 2025-12-22 |
Zojwalla Naseem |
Chief Medical Officer |
Informierter Verkauf |
100,000 |
$28.04 |
$2.8M |
53,997 |
| 2025-12-22 |
Harmon Cyrus |
Director |
Informierter Verkauf |
2,881 |
$28.53 |
$82.19K |
741,259 |
| 2025-12-19 |
Clark Ian T |
Director |
Optionsausübung (Verkauf) |
21,520 |
$3.61 |
$77.69K |
- |
| 2025-12-19 |
Myles David C. |
Ch. Discov. & Non-clin Dev Off |
Schenkung (gegeben) |
9,000 |
- |
- |
542,881 |
| 2025-12-19 |
Zojwalla Naseem |
Chief Medical Officer |
Informierter Verkauf |
12,921 |
$28.93 |
$373.8K |
103,997 |
| 2025-12-08 |
Kovacs Shane William Charles |
Ch. Operating & Financial Off. |
Schenkung (gegeben) |
75,000 |
- |
- |
243,549 |
| 2025-11-26 |
Kovacs Shane William Charles |
Ch. Operating & Financial Off. |
Schenkung (gegeben) |
225,000 |
- |
- |
318,549 |
| 2025-11-25 |
Rappaport Andrew |
Director |
Schenkung (gegeben) |
35,868 |
- |
- |
- |
| 2025-11-21 |
Rappaport Andrew |
Director |
Optionsausübung (Verkauf) |
35,868 |
$0.39 |
$13.99K |
- |
| 2025-09-18 |
Harmon Cyrus |
Director |
Informierter Verkauf |
3,086 |
$8.32 |
$25.68K |
117,028 |
| 2025-09-16 |
Harmon Cyrus |
Director |
Informierter Verkauf |
1,914 |
$8.08 |
$15.47K |
120,114 |
| 2025-06-11 |
Bvf Partners L P/il |
Other: See Explanation of Responses |
RSU-Zuteilung |
24,150 |
$4.08 |
$98.53K |
24,150 |
| 2025-06-11 |
Rappaport Andrew |
Director |
RSU-Zuteilung |
24,150 |
$4.08 |
$98.53K |
24,150 |
| 2025-06-11 |
Butitta Cynthia M |
Director |
RSU-Zuteilung |
24,150 |
$4.08 |
$98.53K |
24,150 |
| 2025-06-11 |
Clark Ian T |
Director |
RSU-Zuteilung |
24,150 |
$4.08 |
$98.53K |
24,150 |
| 2025-06-11 |
Garland J. Scott |
Director |
RSU-Zuteilung |
24,150 |
$4.08 |
$98.53K |
24,150 |
| 2025-06-11 |
Horning Sandra |
Director |
RSU-Zuteilung |
24,150 |
$4.08 |
$98.53K |
24,150 |
| 2025-06-11 |
Graham G. Walmsley |
Director |
RSU-Zuteilung |
24,150 |
$4.08 |
$98.53K |
24,150 |
| 2025-06-11 |
Larson Yi |
Director |
RSU-Zuteilung |
24,150 |
$4.08 |
$98.53K |
24,150 |
| 2025-06-11 |
Hrustanovic Gorjan |
Director |
RSU-Zuteilung |
24,150 |
$4.08 |
$98.53K |
24,150 |
| 2025-06-11 |
Harmon Cyrus |
Director |
RSU-Zuteilung |
24,150 |
$4.08 |
$98.53K |
24,150 |
| 2025-02-28 |
Kovacs Shane William Charles |
Ch. Operating & Financial Off. |
RSU-Zuteilung |
320,000 |
$4.37 |
$1.4M |
320,000 |
| 2025-02-28 |
Mitchell Shawnte |
Chief Legal Officer |
RSU-Zuteilung |
450,000 |
$4.37 |
$1.97M |
450,000 |
| 2025-02-28 |
Myles David C. |
Ch. Discov. & Non-clin Dev Off |
RSU-Zuteilung |
205,000 |
$4.37 |
$895.85K |
205,000 |
| 2025-02-28 |
Bohen Sean |
President and CEO |
RSU-Zuteilung |
650,000 |
$4.37 |
$2.84M |
650,000 |
| 2025-02-28 |
Zojwalla Naseem |
Chief Medical Officer |
RSU-Zuteilung |
205,000 |
$4.37 |
$895.85K |
205,000 |
| 2025-02-18 |
Mitchell Shawnte |
Officer |
Unbekannt |
- |
- |
- |
- |
| 2025-01-10 |
Bain Capital Life Sciences Investors, Llc |
10 Percent Owner |
Sonstige (Kauf) |
3,500,000 |
$0.00 |
$350.00 |
3,500,000 |
| 2025-01-10 |
Bvf Partners L P/il |
Other: See Explanation of Responses |
RSU-Zuteilung |
22,740 |
$0.00 |
$2.27 |
336,288 |
| 2025-01-08 |
Bain Capital Life Sciences Investors, Llc |
10 Percent Owner |
Unbekannt |
- |
- |
- |
7,500,000 |
| 2025-01-08 |
Bain Capital Life Sciences Investors, Llc |
10 Percent Owner |
Informierter Kauf |
300,000 |
$5.76 |
$1.73M |
7,800,000 |
| 2024-12-17 |
Graham G. Walmsley |
Director |
Informierter Verkauf |
700,761 |
$6.75 |
$4.73M |
- |
■ Informativ — Transaktion am offenen Markt (bedeutendste)
■ Nicht-informativ (Kauf) — Vergütung, Optionsausübung, Wandlung
■ Nicht-informativ (Verkauf) — Quellensteuer, Verkauf bei Vesting
■ Neutral — Schenkung, Treuhand, Verfall
